Congress Pushes DEA and FDA to Crack Down on Unregulated Cannabinoids

When you're ready to find a cannabis dispensary near you, Budpedia is the dispensary near me directory built around verified listings, real menus, and city-by-city coverage.

Congressional Committee Sounds the Alarm on Unregulated Cannabis Products

The House Appropriations Committee has released a draft report calling on the Drug Enforcement Administration and Food and Drug Administration to take decisive action against what it describes as a "proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids." The language, included in a spending bill report accompanying the FY2027 appropriations package, signals growing bipartisan concern over a largely unpoliced corner of the cannabis market that has exploded since the 2018 Farm Bill opened the door to hemp-derived products.

The committee's statement is the strongest language yet from Congress on the issue, explicitly framing unregulated cannabinoid products as threats to consumer safety. It arrives at a pivotal moment: the federal government is simultaneously moving cannabis toward Schedule III status while the hemp-derived market operates in a regulatory gray zone that state attorneys general, public health advocates, and licensed cannabis operators have all called dangerous.

What Are Unregulated Intoxicating Cannabinoids?

The products in question include delta-8 THC, delta-10 THC, THC-O acetate, HHC (hexahydrocannabinol), and THCP, among others. These compounds are typically synthesized from hemp-derived CBD through chemical conversion processes, allowing manufacturers to sell intoxicating products while technically remaining within the 2018 Farm Bill's definition of legal hemp — which set the threshold at 0.3 percent delta-9 THC by dry weight.

The result has been a flood of gummies, vapes, tinctures, and beverages sold in gas stations, convenience stores, smoke shops, and online with minimal age verification, no standardized testing requirements, and labels that often bear little resemblance to what's actually inside the package.

Consumer Reports, the FDA, and multiple state health departments have documented cases of products containing residual solvents, heavy metals, and pesticides. Perhaps more concerning, these products are frequently marketed with cartoon characters and candy-like branding that critics say appeals directly to minors.

The Farm Bill Connection

The timing of the congressional push is no accident. The United States is less than eight months away from a major shift in hemp policy. The 2026 Farm Bill, currently advancing through the House Committee on Agriculture, includes language that would tighten the definition of a hemp plant to include a 0.3 percent total THC threshold — meaning total THC including THCA, rather than just delta-9 THC as specified in the 2018 version.

This definitional change would effectively eliminate the legal loophole that has allowed many hemp-derived intoxicating products to reach the market. However, enforcement remains a separate question entirely. Even with tighter definitions on paper, the DEA and FDA would need resources, authority, and political will to police a market that has grown to an estimated several billion dollars annually.

Industry Reactions Are Split

The response from the cannabis industry has been predictably divided along familiar lines. Licensed cannabis operators in state-regulated markets have long argued that hemp-derived intoxicating products undercut their businesses while posing genuine safety risks to consumers. These operators face extensive testing requirements, packaging standards, and tax obligations that their unregulated counterparts do not.

The National Cannabis Industry Association (NCIA) has broadly supported federal efforts to bring intoxicating cannabinoid products under a regulated framework, arguing that the current patchwork approach harms consumers and legitimate businesses alike.

On the other side, hemp industry groups warn that overly broad regulatory action could devastate thousands of small businesses and farming operations that have built their livelihoods around hemp-derived products since 2018. The U.S. Hemp Roundtable has advocated for a regulatory framework that distinguishes between responsible manufacturers who test their products and bad actors who don't, rather than blanket prohibition.

State-Level Patchwork Adds to the Confusion

While Congress deliberates, states have taken wildly different approaches to regulating — or not regulating — hemp-derived intoxicating products. As of May 2026, roughly 20 states have enacted some form of restriction or ban on delta-8 THC and similar compounds, while others have created regulatory frameworks that mirror their adult-use cannabis programs.

Several states, including Colorado and Oregon, have taken the approach of folding hemp-derived intoxicating products into their existing cannabis regulatory frameworks, requiring them to be sold through licensed dispensaries with full testing and labeling requirements. Others, like New York, have attempted bans that have proven difficult to enforce given the ubiquity of online sales.

The result is a confusing patchwork where a product legal in one state may be banned in the next, and where consumers have no consistent way to know whether what they're buying has been tested for safety.

Public Health Concerns Mount

The public health case for action has been building steadily. The FDA has received more than 300 adverse event reports related to delta-8 THC products since 2021, including reports of hospitalizations and cases involving children who accidentally consumed products. Poison control centers have reported a sharp increase in calls related to hemp-derived intoxicating products, particularly among pediatric cases.

A 2025 study published in the Journal of the American Medical Association found that nearly 30 percent of commercially available delta-8 THC products tested contained delta-9 THC levels above the legal 0.3 percent threshold, while a significant portion contained unlisted contaminants from the chemical conversion process.

Medical professionals have also raised concerns about the lack of dosing standardization. Unlike regulated cannabis products, where gummies and edibles are required to contain precise amounts of THC in each serving, hemp-derived products often have wildly inconsistent potency from package to package and even within a single batch.

What Happens Next

The Appropriations Committee's language is a directive, not legislation, meaning it expresses congressional intent but does not carry the force of law. However, it puts both the DEA and FDA on notice that Congress expects action and may follow up with binding requirements if the agencies don't respond.

The DEA has its hands full with the cannabis rescheduling process, which includes a hearing beginning June 29 to evaluate broader changes to marijuana's federal status. Adding enforcement against unregulated cannabinoid products to its agenda would require additional resources and potentially new rulemaking.

The FDA, meanwhile, has been criticized for years for its slow pace in establishing a regulatory framework for CBD and other cannabinoids. The agency has held public hearings, solicited comments, and commissioned studies, but has yet to finalize comprehensive rules for cannabinoid products.

For consumers, the immediate takeaway is straightforward: until federal or state regulators establish clear standards, purchasing cannabinoid products from licensed, state-regulated dispensaries remains the safest option. Products sold outside regulated channels — in gas stations, convenience stores, or online from unknown sellers — carry inherent risks that no amount of attractive packaging can mitigate.

The Bigger Picture

The congressional push against unregulated cannabinoids reflects a broader tension in American cannabis policy: the federal government is simultaneously trying to bring marijuana into a regulated framework through rescheduling while contending with a parallel unregulated market that emerged from hemp legalization. Resolving that tension will require coordination between multiple agencies, alignment between federal and state regulators, and a willingness to invest in enforcement infrastructure.

Whether the Appropriations Committee's language translates into meaningful action remains to be seen. But the direction of travel is clear: the era of unregulated intoxicating cannabinoid products operating in a federal blind spot appears to be drawing to a close.